HOLX News and Press, Hologic Inc. From 01/30/19

Hologic (NASDAQ: HOLX ) fiscal Q1 results ($M): Revenues: 830.7 (+5.0%); U.S. Breast Health: 252.6 (+12.6%). More news on: Hologic, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

Hologic (NASDAQ: HOLX ): Q1 Non-GAAP EPS of $0.58 beats by $0.01 ; GAAP EPS of $0.36 beats by $0.05 . More news on: Hologic, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

– Revenue of $830.7 Million Grows 5.0%, 5.7% in Constant Currency – – Company Posts GAAP Diluted EPS of $0.36, Non-GAAP Diluted EPS of $0.58 – – Company Raises Full-Year Guidance for Constant Currency Revenue and EPS – Hologic, Inc. (Nasda...

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers’ 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers’ regulatory 13F Form filed on 01/29/2019. Please visit our Tracking Kahn Brothers Portfolio series t...

-- FDA clearance makes clinically validated assay available for sexually-transmitted infection listed as emerging threat by the CDC -- Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for its Aptima® Mycoplasma...

Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 29, 2018. The Company expects to report total revenues of approximately $831 million, an increase of 5% compared to the prior year period, or 5.7% in constant currency. Th...

Moderna (NASDAQ: MRNA ) initiated with Buy rating and $25 (64% upside) price target at Goldman Sachs. Initiated with Overweight rating and $22 price target at JPMorgan. Initiated with Overweight rating and $24 price target at Piper Jaffray. Initiated with Overweight rating and $29 price targ...

Flexible, modular design with powerful visualization gives doctors a single device with three sheath options to both diagnose and treat patients Hologic, Inc. (Nasdaq: HOLX) announced today the U.S. launch of its Omni™ hysteroscope , an innovative three-in-one modular scope wi...

Hologic, Inc. (HOLX) Q4 2018 Earnings Call November 07, 2018 4:30 pm ET Executives Michael J. Watts - Hologic, Inc. Stephen P. MacMillan - Hologic, Inc. Karleen Marie Oberton - Hologic, Inc. Analysts Raj Denhoy - Jefferies LLC Isaac Ro - Goldman Sachs & Co. LLC Tych...

Hologic (NASDAQ: HOLX ): Q4 Non-GAAP EPS of $0.58 misses by $0.01 ; GAAP EPS of $0.18 misses by $0.17 . Revenue of $813.5M (+1.3% Y/Y) beats by $6.98M . Shares -1.8% . Press Release More news on: Hologic, Inc., Earnings news and commentary, Healthcare stocks news,